Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial.
Jänne, P van den Heuvel, M Barlesi, F Cobo, M Mazieres, J Crinò, L Orlov, S Wolf, J Garrido, P
Jänne, P
van den Heuvel, M
Barlesi, F
Cobo, M
Mazieres, J
Crinò, L
Orlov, S
Wolf, J
Garrido, P
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial. 2016, 27 (suppl_6):LBA47_PR Annals of Oncology